Atlas Trials

Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

Clinical trial NCT07405164 · RECRUITING

Trial details

NCT number
NCT07405164
Sponsor
Merck Sharp & Dohme LLC
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Von Hippel-Lindau DiseaseMalignant Neoplasms
Start date
2026-03-23
Primary completion
2034-01-14
Enrollment
450

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.